Home Title Index Topic Index Sources Directory News Releases Sources Calendar RSS Sources Select News RSS Feed

Alzheimer Disease/Research
AlterLinks Topic Index

  1. Aging with Grace
    The Nun Study and the Science of Old Age

    Resource Type: Book
  2. Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o
    Sources News Release

    Resource Type: Article
    Published: 2011
    ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
  3. ANAVEX 2-73 advances Phase I clinical trial for Alzheimer’s disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
  4. Anavex adds Dr. Paul Aisen to Scientific Advisory Board
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (OTCBB: AVXL) has announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline
  5. Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheime
  6. Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
    Sources News Release

    Resource Type: Article
    Published: 2010
    Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
  7. Anavex appoints Dr. Jeffrey Cummings to its Scientific Advisory Board
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. has announced the appointment of Dr. Jeffrey Cummings to the Scientific Advisory Board as a clinical expert. The Scientific Advisory Board works closely with the company to support development of the Anavex product pipeline
  8. Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product
  9. Anavex comments on new Alzheimer’s disease diagnostic guidelines
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated
  10. Anavex comments on President Obama’s signing of National Alzheimer’s Project Act into law
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law. The passage of this landmark legislation lays the foundation for the first coordinated national
  11. Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
  12. Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer’s disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled Preclinical development of new tetrahydrofur
  13. Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran deriva
  14. Anavex raises $1.575 million
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the company’s lead drug candidate
  15. Anavex rapidly advances ANAVEX 2-73 for Alzheimer’s disease, Phase I clinical trial progressing well
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. This is the third of six potential dose
  16. Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
  17. Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer’s Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new
  18. Anavex strengthens management team with addition of VP, Clinical Development & Medical Affairs
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announced the addition of Dr. Angelos Stergiou to the executive management team in the role of Vice President, Clinical Development & Medical Affairs. Dr. Stergiou has extensive medical and clinical
  19. Anavex to present at Alzheimer’s Association International Conference on Alzheimer’s Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh
  20. Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York
    Sources News Release

    Resource Type: Article
    Published: 2010
    Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13
  21. Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease
    Sources News Release

    Resource Type: Article
    Published: 2011
    Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
  22. The Lesson
    Resource Type: Article
    Published: 1997
    An educator in a nursing home's essay on Alzheimer's disease.
  23. Musicophilia
    Tales of Music and the Brain

    Resource Type: Book
    Published: 2007
    Oliver Sacks explores the place music occupies in the brain and how it affects the human condition. In Musicophilia, he examines the power of music through the individaul experiences of patients, musicians, and everyday people.
  24. Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
    Sources News Release

    Resource Type: Article
    Published: 2010
    Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.

Experts on Alzheimer Disease/Research in the Sources Directory

  1. The Cochrane Collaboration/The Cochrane Library

Sources-journalists use the sources website to find you


AlterLinks


© 2016. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.